Now Available: Final Rule for FDAAA 801 and NIH Policy on Clinical Trial Reporting
14 studies found for:    ANGIOEDEMA, HEREDITARY, TYPE I
Show Display Options
Rank Status Study
1 Completed A Study to Evaluate the Clinical Efficacy and Safety of Subcutaneously Administered C1-esterase Inhibitor in the Prevention of Hereditary Angioedema
Condition: Hereditary Angioedema Types I and II
Interventions: Biological: Low-volume C1-esterase inhibitor;   Biological: Higher-volume C1-esterase inhibitor;   Biological: Low-volume placebo;   Biological: Higher-volume placebo
2 Unknown  Study to Assess the Tolerability and Safety of Ecallantide in Children and Adolescents With Hereditary Angioedema
Condition: Hereditary Angioedema Types I and II
Intervention: Drug: Ecallantide subcutaneous dosing
3 Active, not recruiting A Study to Evaluate the Long-term Clinical Safety and Efficacy of Subcutaneously Administered C1-esterase Inhibitor in the Prevention of Hereditary Angioedema
Condition: Hereditary Angioedema Types I and II
Intervention: Biological: C1-esterase inhibitor
4 Completed Kinetics, Efficacy and Safety of C1-Esteraseremmer-N
Conditions: Hereditary Angioedema Type I;   Angioneurotic Edema
Intervention: Drug: C1 inhibitor concentrate
5 Completed A Study to Evaluate the Clinical Pharmacology and Safety of C1-esterase Inhibitor Administered by the Subcutaneous Route
Condition: Hereditary Angioedema Types I and II
Interventions: Biological: C1-esterase inhibitor - single intravenous dose;   Biological: C1-esterase inhibitor - subcutaneous low dose;   Biological: C1-esterase inhibitor - subcutaneous medium dose;   Biological: C1-esterase inhibitor - subcutaneous high dose
6 Completed
Has Results
Postmarketing Immunogenicity Study in HAE Subjects Treated With Berinert
Condition: Hereditary Angioedema Types I and II
Intervention: Biological: Berinert, lyophilizate for IV application containing 500 IU C1-INH to be reconstituted with 10 mL water for injection
7 Completed A Study to Evaluate the Safety and Pharmacokinetics of Two Formulations of C1-esterase Inhibitor
Condition: Hereditary Angioedema Types I and II
Interventions: Biological: Berinert;   Biological: CSL830
8 Completed A Study to Evaluate the Safety and Efficacy of HAE1 in Subjects With Moderate to Severe Allergic Asthma
Condition: Allergic Asthma
Intervention: Drug: HAE1 (PRO98498)
9 Completed C1-Esteraseremmer-N for the Treatment of Hereditary (and Acquired) Angioedema
Condition: Angioedema
Intervention: Drug: C1 inhibitor concentrate (C1-esteraseremmer-N)
10 Completed C1-Esteraseremmer-N for the Treatment of Hereditary (and Acquired) Angioedema
Condition: Angioedema
Intervention: Drug: C1 inhibitor concentrate (C1-esteraseremmer-N)
11 Active, not recruiting Efficacy and Safety Study of DX-2930 to Prevent Acute Angioedema Attacks in Patients With Type I and Type II HAE
Condition: Hereditary Angioedema
Interventions: Drug: DX-2930 - 300mg/2wk;   Drug: DX-2930 - 300mg/4wk;   Drug: DX-2930 150mg/4wk;   Drug: Placebo
12 Enrolling by invitation Long-term Safety and Efficacy Study of DX-2930 to Prevent Acute Angioedema Attacks in Patients With Type I and Type II HAE
Condition: Hereditary Angioedema
Intervention: Drug: DX-2930
13 Completed
Has Results
A Study of Icatibant in Patients With Acute Attacks of Hereditary Angioedema (FAST-3)
Condition: Hereditary Angioedema
Interventions: Drug: Icatibant;   Drug: Placebo
14 Completed
Has Results
EASSI - Evaluation of the Safety of Self-Administration With Icatibant
Condition: Hereditary Angioedema
Intervention: Drug: Icatibant

Study has passed its completion date and status has not been verified in more than two years.